Skip to content

News

Topline results for Asarina Pharma’s phase IIb study in Sepranolone for PMDD, released in April 2020, found that Sepranolone failed to meet its primary...
Asarina Pharma’s Clinical Trial Application for its phase IIa study in Tourette Syndrome was approved by the Danish Medical Agency in May 2021 and...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME OCD For further information, please contact: Peter Nordkild, CEO Phone: +45...
CEO Peter Nordkild: “Obviously we had hoped for a different outcome. This solid clinical study unfortunately does not confirm the scientific hypothesis...
The new patent is valid until 2038. Tourette and OCD are common co-morbidities, both with strong compulsion mechanisms. In March 2021 Asarina Pharma shared...
The convertible loan supplements Asarina Pharma’s current financial resources and will be spent on further exploration of the potential of Sepranolone...
Each warrant gives the holder the right to subscribe to one new Asarina share at a fixed price of SEK 9.87 (150% of the average share price during the...
With Cognitive Behavioral Therapy as first-line treatment for Tourette, and many pharma treatments exhibiting severe side effects, there is a large unmet...
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME For further information, please contact: Peter Nordkild, CEO Phone: +45 25...
Adoption of income statement and balance sheet and discharge from liability The AGM resolved to adopt the income statement for the financial year 2020...